Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03410485
Other study ID # CER15083
Secondary ID CAS-2016-010
Status Recruiting
Phase N/A
First received October 11, 2016
Last updated January 18, 2018
Start date October 2016
Est. completion date December 2018

Study information

Verified date January 2018
Source Maisonneuve-Rosemont Hospital
Contact Philippe Richebé, MD, PhD
Phone +1-514-743-6558
Email philipperichebe@live.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

So far, only vital signs (mostly, blood pressure and heart rate) helped the anesthesiologist to administer hypnotic agents or analgesics. Many devices have offered pain monitoring for anesthetized patients, the most recent being the PMD200 device and its NoL index. The BIS index is widely used for depth of anesthesia monitoring. The hypothesis of this study is that the intraoperative combination of both the NoL and the BIS indices to guide the delivery of opioids and hypotonics respectively, will improve the quality of recovery as well as the safety after anesthesia in ERAS patients undergoing colonic surgery.


Description:

Hypothesis is that the intraoperative use of the combination of 1) the NoL index (given by the PMD200TM monitor, Medasense LTD inc, Ramat, Israel) to monitor pain levels and to guide opioids' administration during surgery, and 2) the BIS index (Medtronic, St-Laurent, QC, Canada) to monitor the depth of hypnosis during anesthesia and to guide the administration of anesthetic halogenous gases, will improve the quality of recovery as well as the safety after anesthesia in ERAS (Early Rehabilitation After Surgery) patients undergoing colonic surgery under general anesthesia + epidural analgesia.

This study will compare a group of patients monitored by the classical monitoring (with anesthesia/analgesia guided by these classical parameters: heart rate, blood pressure; Control "C" group; no BIS, no NoL) to a group of patients monitored by the same classical monitoring implemented with the NoL/BIS indices (with analgesia/anesthesia guided by these 2 indices; Monitoring "M" group).

The primary objective of the study will be the total consumption of desflurane that is expected to be significantly reduced in the M group. Secondary objectives will be evaluating safety and side effects of anesthesia and opioids and we expect a reduction of the following parameters: time for awakening from anesthesia, time for extubation, time for transfer to PACU, intraoperative opioid consumption, opioid consumption in PACU and for 48h, time for readiness for discharge from PACU, incidence of adverse effects such as: nausea-vomiting / sedation / respiratory depression / itching / dizziness / cognitive dysfunction in PACU and for 48h, satisfaction of the patients at 24 and 48hs, pain scores at rest and at mobilization in PACU, at 24h and 48h. Quality of postoperative recovery after surgery and treatment satisfaction are also expected to be higher in the M group than in the C group.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 2018
Est. primary completion date September 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- ASA status I, II or III

- Patients aged 18 years

- Colo-rectal surgery

- Duration and type of surgery requiring an epidural analgesia via an epidural catheter placed prior the general anesthesia induction and an arterial line placed after induction of general anesthesia (classical management of ERAS program patients in our center)

Exclusion Criteria:

- chronic arhythmic condition

- chronic pain

- Adverse events prompting termination of protocol:

- Unexpected difficult airway requesting excessive, possibly painful airway manipulations.

- Unexpected surgical complications requiring strong haemodynamic support (transfusions, volume challenges, vasopressors, inotropic drugs)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
BIS index/NoL index
Remifentanil i.v. infusion will be run between 0.03 and 0.15 mcg/kg/min and boluses (0.4mcg/kg) will be given to keep a NoL index between 10-20. Once intubated, the maintenance of anesthesia will be achieved with: desflurane set at 1 MAC to start, then adapted to the BIS between 45-55.
Variation of baseline mean arterial pressure
Remifentanil i.v. infusion will be run between 0.03 and 0.15 mcg/kg/min and boluses (0.4mcg/kg) will be given to keep a baseline mean arterial pressure between 10% of variation. Once intubated, the maintenance of anesthesia will be achieved with: desflurane set at 1 MAC to start, then ajusted to 0.8 MAC.

Locations

Country Name City State
Canada Hopital Maisonneuve Rosemont, CIUSSS de l'Est de l'Ile de Montreal Montreal Quebec

Sponsors (3)

Lead Sponsor Collaborator
Maisonneuve-Rosemont Hospital Canadian Anesthesiologists' Society, Medasense Biometrics Ltd

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total desflurane consumption Total consumption and absorption in ml/kg/h of desflurane in group C versus group M 10 hours
Secondary Hourly desflurane consumption Consumption and absorption of desflurane in ml/kg/h for each hour of surgery. These data are given by the Drager Perseus A500 ventilator per second during the surgery. 10 hours
Secondary Total remifentanil consumption mcg/h Total consumption of i.v. remifentanil during surgery and for each hour of surgery 10 hours
Secondary Hypotensive events Total number of hypotensive events during surgery defined as mean blood pressure below 10% of baseline 10 hours
Secondary Total phenylephrine consumption mcg/h Total doses of intraoperative infused i.v. phenylephrine and doses per hour 10 hours
Secondary Emergence time (seconds) Time for awakening (eyes opening) at the end of the surgery, time for extubation, time for transfer to the PACU in seconds 30 min
Secondary Acute pain (NRS scores on scale from 0 to 10) NRS scale pain score at rest 48 hours postoperatively
Secondary Analgesic requirement (total ml of epidural solution consumption) cumulative dose over 48hs 48 hours postoperatively
Secondary Nausea and vomiting on Nausea and vomiting scale from 0 to 4, cumulative scores over 48hours 48 hours postoperatively
Secondary Postoperative sedation On POSS (postoperative sedation score) scale from 0 to 5, cumulative over 48 hours 48 hours postoperatively
Secondary Postoperative respiratory depression yes or no (1 or 0) for 48 hours 48 hours postoperatively
Secondary PACU discharge time in minutes Time for readiness for PACU discharge based on Aldrete scores superior to 9. 3 hours
Secondary Postoperative cognitive dysfunction Assessment of perioperative cognitive function using the classical MMSE scores over 5 days 5 days postoperatively
Secondary Postoperative delirium Assessment of perioperative Delirium with NuDESC score over 5 days after surgery 5 days postoperatively
Secondary Postoperative analgesia hydromorphone rescue Total hydromorphone rescue doses for 5 days, and total epidural doses in ml as continuous infusion + boluses (PCEA) 5 days postoperatively
Secondary Recovery after surgery score on scale QOR15 (scale 0 to 150) Patients' perceived quality of recovery from anesthesia with QoR-15 5 days postoperatively
Secondary Postoperative chronic pain (score 0 to 10) Presence and severity of persistent postoperative pain with DN4 questionnaires 6 months postoperatively
Secondary Postoperative chronic pain (scale 0 to 60) Presence and severity of persistent postoperative pain SF-MPQ questionnaires 6 months postoperatively
Secondary Mortality Rate of hospital mortality up to 6 months following surgery 6 months postoperatively
Secondary Readmission Rate of hospital readmission up to 6 months following surgery 6 months postoperatively
Secondary POCD/POD related inflammatory cytokines Blood sample will be drawn and cytokines related to POCD/POD will be measured 24h postoperatively
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05559255 - Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI N/A
Completed NCT04748367 - Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care N/A
Terminated NCT04356352 - Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain Phase 2/Phase 3
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04466111 - Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05868122 - A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy Phase 3
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Completed NCT03273114 - Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain N/A
Enrolling by invitation NCT06087432 - Is PNF Application Effective on Temporomandibular Dysfunction N/A
Completed NCT05508594 - Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 Phase 2/Phase 3
Recruiting NCT03646955 - Partial Breast Versus no Irradiation for Women With Early Breast Cancer N/A
Active, not recruiting NCT03472300 - Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
Completed NCT03678168 - A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries N/A
Completed NCT03286543 - Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System N/A
Completed NCT03931772 - Online Automated Self-Hypnosis Program N/A
Completed NCT02913027 - Can We Improve the Comfort of Pelvic Exams? N/A
Terminated NCT02181387 - Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor? Phase 4
Recruiting NCT06032559 - Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment Phase 3
Active, not recruiting NCT03613155 - Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care